Clinical trials: Double-blind Design
Diabetes Mellitus Type 2
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
This exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients…
- Trial name
- NCT02373865
- Testing
- Sitagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- GWT-TUD GmbH
Actinic Keratosis
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis
- Trial name
- NCT01962987
- Testing
- Diclofenac sodium
- Where
- 31 sites in United States
- Volunteers
- 476 people
- Sponsor
- Actavis Inc.
Neuromuscular Blockade
Effectiveness of Deep Versus Moderate Neuromuscular Blockade
The aim of this study is to evaluate the influence of depth of neuromuscular blockade during laparoscopic gastrectomy on postoperative pain in surgical patients allocated randomly to either deep or moderate neuromuscular blockade…
- Trial name
- NCT03266419
- Testing
- Deep NMB using rocuronium, Moderate NMB using rocuronium
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01335997
- Testing
- ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM)
- Volunteers
- 1,139 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyspareunia
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
- Trial name
- NCT05617820
- Testing
- Estradiol, Imvexxy
- Where
- 48 sites in United States, El Salvador and 1 more
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Osteoporosis, Postmenopausal
Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND
This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in…
- Trial name
- ALVOBOND (NCT05395091)
- Testing
- AVT03, Denosumab
- Where
- 34 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 532 people
- Sponsor
- Alvotech Swiss AG
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Erectile Dysfunction
Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED
To evaluate the safety and efficacy of a single intracavernous injection of hMaxi K (8000 µg and 16000 µg) or placebo upon penile rigidity or erection in males with erectile dysfunction longer than six months that is attributable…
- Trial name
- NCT02713789
- Testing
- hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)
- Where
- Kuwait
- Volunteers
- 26 people
- Sponsor
- Urovant Sciences GmbH
Clostridium Difficile Infection
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
This study will investigate whether: 1) treatment with MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium difficile infection (CDI) recurrence as compared to treatment with MK-6072 or…
- Trial name
- MODIFY I (NCT01241552)
- Testing
- MK-3415, MK-6072, MK-3415A
- Volunteers
- 1,452 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Hyperactivity Disorder
PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
This is PART B of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03609619
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Asthma
AZD1419 Ph2a Study
Ph2a study planned to be run at approximately 16-18 sites in 4 EU countries (Denmark, Hungary, Poland and Sweden) enrolling approximately 170 patients to ensure 70 randomized patients with eosinophilic, moderate to severe asthma.
- Trial name
- INCONTRO (NCT02898662)
- Testing
- AZD1419
- Where
- 15 sites in Denmark, Hungary and 2 more
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Obesity
ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
The purpose of this clinical research trial is to study safety and effectiveness of the TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered medically obese.
- Trial name
- NCT02518685
- Testing
- TransPyloric Shuttle, Lifestyle Counseling
- Where
- 9 sites in United States
- Volunteers
- 302 people
- Sponsor
- BaroNova, Inc.
Benign Prostatic Hyperplasia (BPH)
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00970632
- Testing
- Tadalafil 5 mg, Tamsulosin
- Where
- 44 sites in Australia, Austria and 8 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Stroke, Acute
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen…
- Trial name
- ESCAPE-NEXT (NCT04462536)
- Testing
- Nerinetide
- Where
- 81 sites in United States, Australia and 7 more
- Volunteers
- 850 people
- Sponsor
- NoNO Inc.
Schizophrenia
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of…
- Trial name
- NCT04959032
- Testing
- Lumateperone 42 mg
- Where
- 43 sites in United States, Bulgaria and 2 more
- Volunteers
- 592 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
The objective of the randomised part of the study is to investigate the efficacy and safety of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug naive or previously treated (4 weeks…
- Trial name
- NCT00798161
- Testing
- BI 1356, BI 1356 + metformin, Metformin
- Where
- 138 sites in Canada, Croatia and 12 more
- Volunteers
- 857 people
- Sponsor
- Boehringer Ingelheim
Coronavirus Disease 2019
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
- Trial name
- NCT04347239
- Testing
- Leronlimab (700mg)
- Where
- 18 sites in United States
- Volunteers
- 484 people
- Sponsor
- CytoDyn, Inc.
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).
- Trial name
- NCT06262607
- Testing
- CLE-400, Vehicle
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Clexio Biosciences Ltd.
Nicotine Dependence
Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention
The purpose of this research study is to find out if an investigational drug, GSK598809 can help people who have very recently quit smoking; the investigators want to find out if continuing to take GSK598809 over six weeks can…
- Trial name
- NCT01188967
- Testing
- GSK598809
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital